June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Corneal Collagen Crosslinking in the Save Sight Keratoconus Registry: Epithelium on or off?
Author Affiliations & Notes
  • Grace A Borchert
    The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia
    Princess Alexandra Hospital, Brisbane, Queensland, Australia
  • Himal Kandel
    The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia
  • Aanchal Gupta
    Adelaide Eye & Laser Centre, Adelaide, South Australia, Australia
    South Australian Institute of Ophthalmology, Adelaide, South Australia, Australia
  • Jern Yee Chen
    Flinders Medical Centre, Adelaide, South Australia, Australia
  • Yves Kerdraon
    The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia
  • Richard A Mills
    Flinders Medical Centre, Adelaide, South Australia, Australia
  • Stephanie L Watson
    The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia
  • Footnotes
    Commercial Relationships   Grace Borchert None; Himal Kandel None; Aanchal Gupta None; Jern Yee Chen None; Yves Kerdraon None; Richard Mills None; Stephanie Watson None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 1677. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Grace A Borchert, Himal Kandel, Aanchal Gupta, Jern Yee Chen, Yves Kerdraon, Richard A Mills, Stephanie L Watson; Corneal Collagen Crosslinking in the Save Sight Keratoconus Registry: Epithelium on or off?. Invest. Ophthalmol. Vis. Sci. 2023;64(8):1677.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Primary treatment for progressive keratoconus is corneal collagen crosslinking (CXL). Patients having CXL are seeking answers whether they should have epithelium off or epithelium on CXL. The aim of this study was to assess the efficacy and safety of epithelium-off and epithelium-on CXL protocols in keratoconus.

Methods : A prospective observational study was performed using real-world data of patients in routine clinical practice from the Save Sight Keratoconus Registry. Patients who were from Australia and had no prior intervention before CXL were included. Primary outcomes were change in Kmax, habitual corrected visual acuity (VA), K2, and minimum corneal thickness (MCT) at 12 months follow-up. Mixed effects regression models were used to evaluate changes in outcomes adjusted for age, sex, baseline outcomes, eye laterality and practices.

Results : There were 49 eyes (37 patients) and 1170 eyes (888 patients) in the epithelium-on and epithelium-off CXL protocols, respectively. The mean age was comparable between the epithelium-on and epithelium-off group, 26 (SD 8.9) vs 25.9 (SD 7.4) years, respectively. At 12 months from the baseline, the mean change in Kmax was 0.4D (95% CI: -0.6, 1.4) with epithelium-on CXL vs 0.1D (-0.1, 0.3) with epithelium-off CXL. For epithelium-on CXL vs epithelium-off CXL respectively, the mean change in VA from baseline to 12 months was 1.0 (-0.8, 2.7) logMAR letters vs 0.7 (0,1.3) logMAR letters and change in K2 was -0.1D (-0.6,0.5) vs 0.1D (-0.1,0.2) in epithelium-on and off CXL which were not statistically significant (all p <0.05). The epithelium off group had greater corneal thinning with an MCT change of -14.3 µm (-16.2, -12.5) vs 0.5µm (-4,5.4) in the epithelium-on group (p <0.001). There were less adverse events recorded in epithelium-on relative to epithelium-off CXL.

Conclusions : Epithelium-off and epithelium-on CXL protocols were similarly effective, as measured by VA and corneal curvature, in preventing keratoconus progression from the baseline to 12 months follow up.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×